[go: up one dir, main page]

WO2004056821A3 - Quinolizidine derivatives - Google Patents

Quinolizidine derivatives Download PDF

Info

Publication number
WO2004056821A3
WO2004056821A3 PCT/EP2003/014561 EP0314561W WO2004056821A3 WO 2004056821 A3 WO2004056821 A3 WO 2004056821A3 EP 0314561 W EP0314561 W EP 0314561W WO 2004056821 A3 WO2004056821 A3 WO 2004056821A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinolizidine derivatives
quinolizidine
derivatives
neurological
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/014561
Other languages
French (fr)
Other versions
WO2004056821A2 (en
Inventor
Desmond John Best
Barry Sidney Orlek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU2003290095A priority Critical patent/AU2003290095A1/en
Publication of WO2004056821A2 publication Critical patent/WO2004056821A2/en
Publication of WO2004056821A3 publication Critical patent/WO2004056821A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel quinolizidine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
PCT/EP2003/014561 2002-12-20 2003-12-18 Quinolizidine derivatives Ceased WO2004056821A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003290095A AU2003290095A1 (en) 2002-12-20 2003-12-18 Quinolizidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0229822A GB0229822D0 (en) 2002-12-20 2002-12-20 Novel compounds
GB0229822.2 2002-12-20

Publications (2)

Publication Number Publication Date
WO2004056821A2 WO2004056821A2 (en) 2004-07-08
WO2004056821A3 true WO2004056821A3 (en) 2004-08-12

Family

ID=9950166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/014561 Ceased WO2004056821A2 (en) 2002-12-20 2003-12-18 Quinolizidine derivatives

Country Status (3)

Country Link
AU (1) AU2003290095A1 (en)
GB (1) GB0229822D0 (en)
WO (1) WO2004056821A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003302A1 (en) * 1993-07-20 1995-02-02 Smithkline Beecham Plc Quinolizidines with calcium channel antagonistic activity
WO2002024695A2 (en) * 2000-09-22 2002-03-28 Ortho Mcneil Pharmaceutical, Inc. Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003302A1 (en) * 1993-07-20 1995-02-02 Smithkline Beecham Plc Quinolizidines with calcium channel antagonistic activity
WO2002024695A2 (en) * 2000-09-22 2002-03-28 Ortho Mcneil Pharmaceutical, Inc. Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines

Also Published As

Publication number Publication date
AU2003290095A8 (en) 2004-07-14
AU2003290095A1 (en) 2004-07-14
WO2004056821A2 (en) 2004-07-08
GB0229822D0 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
TW200500344A (en) Novel compounds
WO2002041889A3 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
WO2000035919A3 (en) Quinoline derivatives
GB0329214D0 (en) Novel compounds
TW200503713A (en) Novel compounds
TW200503710A (en) Novel compounds
GB0111186D0 (en) Novel compounds
MY138836A (en) Quinoline derivatives and their use as 5-ht6 receptor ligands
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
MY133392A (en) Novel substituted pyrazole derivatives
WO2004009590A8 (en) 4-amino-substituted pyrimidine derivatives
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
HK1054032A1 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2003000699A8 (en) Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
TW200621716A (en) Novel compounds
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
TW200514781A (en) Novel compounds
IL188184A0 (en) Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists
GB0420831D0 (en) Novel compounds
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
CA2474511A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
TW200611701A (en) Novel compounds
GB0320320D0 (en) Novel compounds
GB0322510D0 (en) Novel compounds
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP